DocWire News Editors

DocwireNews

A study published in Blood found that concurrent treatment with ibrutinib and CD19 chimeric antigen receptor (CAR) T-cells was well tolerated, associated with low cytokine release syndrome (CRS) severity, and resulted in a high rate of negative minimal residual disease in patients with chronic lymphocytic leukemia (CLL).The study included 19 patients who received a median of five prior therapies. Most patients (n=17; 89%) had high-risk cytogenetics. Ibrutinib treatment was initiated two or more weeks before leukapheresis and continued for three or more months following CAR T-cell infusion.Thirteen patients (68%) received ibrutinib as planned without dose reduction. The four-week overall response rate was 83%. Close to two-thirds of patients (61%) achieved a minimal residual disease (MRD)-negative marrow response by&nbsp;IGH&nbsp;sequencing. Among these patients, the one-year overall survival and progression-free survival (PFS) probabilities were 86% and 59%, respectively.The results showed that, when compared with CLL patients treated with CAR T-cells without ibrutinib, the concurrent treatment was linked to reduced CRS severity and lower serum concentrations of CRS-associated cytokines, despite equivalent in vivo CAR T-cell expansion. Among all evaluable patients, one-year PFS probability was 38% in patients treated with ibrutinib and CAR T-cell therapy versus 50% CAR T-cell therapy alone (P=0.91).

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

MRD Negativity Associated with Ibrutinib Plus CAR T-Cell Treatment for CLL

Oncology

A study published in Blood found that concurrent treatment with ibrutinib and CD19 chimeric antigen receptor (CAR) T-cells was well tolerated, associated with low cytokine ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe